Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
June 03, 2023 07:00 ET
|
Immunocore Holdings Limited
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3...
Immunocore to present at upcoming investor conferences
June 01, 2023 16:30 ET
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 June 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Companion Diagnostics Market to Expand at a CAGR of 9% during Forecast Period: TMR Study
April 21, 2023 08:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, April 21, 2023 (GLOBE NEWSWIRE) -- The global companion diagnostics market size stood at USD 5.24 Bn in 2020 and is estimated to reach USD 9.30 Bn by 2028. The...
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
April 18, 2023 09:00 ET
|
Immuneering Corporation
Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or...
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
April 18, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival In the Phase 3 trial, early on-treatment ctDNA reduction was strongly associated...
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023 16:05 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immunocore to present four posters at AACR Annual Meeting 2023
March 14, 2023 16:30 ET
|
Immunocore Holdings Limited
Immunocore to present four posters at AACR Annual Meeting 2023 Updated three-year overall survival data for tebentafusp-tebn in previously treated metastatic uveal melanoma Phase 3 data showing...
Immuneering Announces Participation in March Investor Conferences
February 28, 2023 08:00 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Immunocore to present at upcoming investor conferences
February 28, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 28 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a...
Cytovation announces first patient dosed in Phase 2a study investigating CyPep-1 monotherapy in advanced melanoma refractory to checkpoint inhibitors
February 15, 2023 03:00 ET
|
Cytovation
Bergen, Norway, 15 February 2023 – Cytovation ASA, a clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces...